RobertB.BhisitkulMD
Ophthalmology • San Francisco, CAProfessor, Ophthalmology, UCSF School of Medicine
Dr. Bhisitkul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-472-1000Fax+1 415-353-2564- Is this information wrong?
Education & Training
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Transitional Year, 1992 - 1993
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1998 - 2026
MA State Medical License 1996 - 1999- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery Start of enrollment: 2008 Apr 01
- Seven Year Update of Macular Degeneration Patients Start of enrollment: 2010 Dec 01
Publications & Presentations
PubMed
- Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vis...Blotner, S., Quezada-Ruiz, C., Haskova, Z., Bhisitkul, R., Campochiaro, P., Liu, M.> ;The British Journal of Ophthalmology. 2024 Jan 30
- Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study.Daniel S Pereira, Kazumasa Akita, Robert B Bhisitkul, Toshiaki Nishihata, Yusuf Ali, Emiko Nakamura, Yoshikazu Nakamura> ;Eye. 2024 Apr 1
- Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.Daniel S Pereira, Raj K Maturi, Kazumasa Akita, Vinaya Mahesh, Robert B Bhisitkul, Toshiaki Nishihata, Eri Sakota, Yusuf Ali, Emiko Nakamura, Padma Bezwada, Yoshikazu ...> ;Eye. 2024 Apr 1
- Join now to see all
Press Mentions
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaMarch 23rd, 2023- UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the EyeOctober 11th, 2022
- UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye DiseaseNovember 9th, 2021
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
UCSF Medical CenterSan Francisco, California
Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, California
San Francisco VA Medical CenterSan Francisco, California
St. Mary's Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
